We have not found any cost information for this lawyer
About Jennifer
Biography
Media Mentions:
-
Quoted, “Patently vulnerable,” BioCentury, The Bernstein Report on BioBusiness, August 8, 2011
-
Quoted, “Myriad gene patent: recent court ruling to resonate with gene and stem patent holders, labs offering sequencing, experts say,” BioPharm Insight, August 8, 2011
-
Quoted, “Patent Community Sees Post-Myriad Issues’ Expects Either En Banc or High Court Review,” BNA’s Patent Trademark & Copyright Journal, August 5, 2011
-
Quoted, “Biotech Sizes up Federal Circuit Ruling in Myriad Case,” BioWorld Today, August 2, 2011
-
Quoted, “The Big Fight,”Genome Technology, July 2, 2011
-
Quoted, "Bay State Comes Out Ahead in Biotech Venture Funding," Boston Business Journal, October 8, 2010
-
Prominent Mention, "Changing Places," Mass High Tech, July 21, 2010
-
Featured Interview, "On The Cutting Edge of Biotech Law," The Metropolitan Corporate Counsel, June 2010
-
Featured Interview, "IP Law, Biotech and Business and Coping with Bilski and KSR," The Metropolitan Corporate Counsel, February 2009
-
Featured Interview, "Biotech Co. Counsel Moves Back to Proskauer," Law360, March 10, 2008
-
Quoted, "As Liability Grows, GCs Get Nervous," National Law Journal, September 25, 2006
-
Prominent Mention, "Codon Devices," Harvard Business School Case, June 5, 2006
Practice Areas
Fees and Rates
Looking for an attorney? Avvo can help.
Search our directory
Quickly connect with top attorneys through our legal directory to get help with your legal issue.
Avvo's live chat agents can help coordinate a consultation with a local attorney.
Chat with a live agent who can match you with the right attorney for your legal needs.
Chat withLicenses
Licensed in Massachusetts for 28 years
State: Massachusetts
Acquired: 1997
No misconduct found
Location
Greenberg Traurig, LLP
One International Place, Boston, MA, 02110-2600
Ad
Transform legal challenges into solutions.
Connect now to review your situation.
Jennifer A. Camacho's Reviews
Avvo Review Score
Not Yet Reviewed
Jennifer A. Camacho's Lawyer Endorsements
"Jennifer is an outstanding intellectual property lawyer with strong technical expertise in life sciences. She is especially skilled in offering practical, business-savvy advice. I highly endorse Jennifer."
"Jennifer is an exceptional attorney. She brings to bear a wealth of experience handling IP issues for life sciences companies. Her advice is refreshingly practical and constructive."
"I endorse this lawyer."
"I endorse this lawyer. Smart pracitcal solutions combined with deep knowledge of the subject matter. A great combination."
"I endorse this lawyer."
Christopher Chung
Intellectual property lawyer
Robert Blasi
Intellectual property lawyer
Stephen Adams
Corporate and incorporation lawyer
Robert Puopolo
Life sciences and biotechnology lawyer
Experience
Honors
2011
2011 Tech Luminary, Mass High Tech Business News and Boston Business Journal
Work Experience
2010 - Present
Shareholder, Greenberg Traurig LLP
2008 - 2010
Partner, Proskauer Rose, LLP
2005 - 2008
VP of IP, Chief Patent Counsel, GC and Corpoate Secretary, Codon Devices, Inc.
2004 - 2005
Associate, Proskauer Rose LLP
1997 - 2004
Associate, Testa Hurwitz & Thibeault
Associations
2010 - Present
MassChallenge, Inc. Annual Startup Competition and AcceleratorJudge and Mentor
2009 - Present
The Center for Policy on Emerging TechnologiesBoard of Directors
2008 - Present
Boston College Law School Business Advisory CouncilCouncil Member
2008 - Present
Women Entrepreneurs in Science and TechnologyMember
2000 - Present
American Intellectual Property Law AssociationMember
1997 - Present
Boston Patent Law AssociationMember
1997 - Present
Boston Bar AssociationMember
Education
N/A
Boston College Law School
JD - Juris Doctor
N/A
University of Illinois, Urbana-Champaign
BS - Bachelor of Science
Speaking Engagements
2012
6th Tactical and Practical Guide to Freedom to Operate
The Master Class on Creating and Implementing an Iterative FTO Strategy: Utilizing FTO to Inform Product Development and Minimize IP Risks
2012
16th Annual Advanced Forum on: Structuring, Analyzing and Negotiating Life Sciences Collaborative Agreements and Acquisitions
What the U.S. Patent Reform Act Means for Deal-Makers and Business Development Strategies
2011
2011 National Biotechnology Conference
IP and Data Exclusivity in the New Biosimilars Regulatory Framework
2008
Legal and Regulatory Issues
The Life Sciences Boom – Is Innovation and Transformation Enough to Maintain the Massachusetts Edge
2008
Biotechnology Policy Issues
The Future of Science and Technology, a Forum on the Presidential Election
2003
Your Intellectual Property Team & Strategies
Profiting from Your IP
Publications
2012
Nature Biotechnology
Biotech Innovaton in a First-to-File World: You May Win the Race, but Can You Take Home the Prize?
2011
Intellectual Property & Technology Law Journal
Myriad and the Patent-Eligibility of Genetic Inventions: What’s the Matter Under 35 U.S.C. § 101?
2011
BNA's Patent, Trademark & Copyright Journal
How to Get the Most From the PTO's Full First Action Interview Pilot Program
2010
Prior Firm Client Alert
Implication for Biotechnology Enterprises and Investors as District Court Invalidates Cancer Gene Patents
2008
Prior Firm Client Alert
In re Bilski: Federal Circuit Affirms Patent Office in Narrowing Scope of Patentable Subject Matter
2004
Prior Firm Client Alert
Federal Circuit Holds That in Determining Whether Infringement of a Patent Was Willful, Clients Can Now Assert Their Attorney-Client Privilege Without Risk of an Adverse Inference That a Legal Opinion Was Negative
2004
The Journal of BioLaw & Business
Taking a Global View of a Life Sciences Company’s Patent Positio
2002
Intellectual Property Observer
Gene Patents: Testing the Limits
2002
The Journal of BioLaw & Business
E-Rights: Wagging the Electronic Tale
2001
Intellectual Property Observer
Navigating the Complicated Terrain of Joint Ownership
1995
Molecular Reproductive Development
Production of Live Offspring with Predicted Genotypes Using PCR-RFLP Analysis of Polar Bodies From Mouse Oocytes
1991
Neuroscience Letters
The Effect of Ca2+ Channel Antagonists (Cadmium, ω-Conotoxin, GIVA, and Nitrendipine) on the Release of Angiotensin II from Fetal Rat Brain Cell Culture In Vitro
1990
Neuroscience Abstracts
The Release of Angiotensin Following Isoproternol, Cholera Toxin, Forskolin and Phorbol Ester Stimulation of Fetal Rat Brain in Culture
1990
Society for Neuroscience Abstracts
The Role and Potential Interaction of Adenylate Cyclase, Protein Kinase C, and Calmodulin on Angiotensin Release from Dissociated Brain Cell Cultures
Languages
English